Description: Spectral Medical Inc., formerly Spectral Diagnostics Inc., is a therapeutic development company. The Company is focused on the development and commercialization of a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) and the Toraymyxin (PMX) therapeutic. The Company also manufactures and sells certain reagents. The Company develops biochemical markers for the clinical syndrome known as septic shock. PMX is a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. The Company develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies through non-exclusive license and supply agreements.
Home Page: www.spectraldx.com
EDT Technical Analysis
135 The West Mall
Toronto,
ON
M9C 1C2
Canada
Phone:
416-626-3233
Officers
| Name | Title |
|---|---|
| Mr. Christopher Seto | CEO & Director |
| Dr. John A. Kellum M.D. | Chief Medical Officer |
| Ms. Debra-Anne M. Foster B.Sc., RN, CCRC | VP of Clinical Devel. |
| Mr. Blair McInnis | Chief Financial Officer |
| Mr. Sam Amory | Pres of Dialco Medical Inc. |
Exchange: TO
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 49.8661 |
| Price-to-Sales TTM: | 56.1122 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 31 |